•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing agreement with Denmark-based Zealand Pharma (CPH: ZEAL). The partnership aims to develop and commercialize petrelintide, Zealand Pharma’s amylin analog, both as a standalone therapy and in a fixed-dose combination with Roche’s lead incretin asset CT-388.…
•
The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control and Prevention Administration jointly released a notification to guide the informatization function of compact county-level medical communities. This initiative aims to enhance healthcare service integration and efficiency at the county level through advanced information technology.…
•
China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for generic drug quality and consistency evaluation (GQCE). This update is part of the ongoing efforts to standardize and improve the quality of generic drugs in the country. New Additions and RejectionsThe latest batch includes 59…
•
China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation for Neurological Medical Services (Trial)”, aimed at guiding provincial healthcare security administration bureaus to formulate unified provincial price benchmarks. This initiative integrates the current pricing items for the nervous system into 82 items, including 24…
•
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues of HKD 11.64 billion (USD 1.5 billion), marking a 12.8% year-on-year increase. Net profits reached HKD 2.47 billion (USD 318 million), up 34% from the previous year. Based on this strong performance, the company plans…
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An Good Doctor, released its 2024 financial report. The company recorded RMB 4.8 billion (USD 664 million) in revenues, marking a 2.9% year-on-year (YOY) increase. Notably, Ping An Healthcare achieved a significant turnaround by posting RMB88.32…
•
China-based Jiuzhitang Co. Ltd (SHE: 000989) announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic product, human bone marrow mesenchymal stem cells (hBMSCs), to treat autism spectrum disorder (ASD). This marks a significant step forward in exploring novel therapeutic options for ASD.…
•
Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi Holdings Limited (HKG: 2228), a global leader in AI+ automation technology platforms. This investment will fuel the deep integration of Newdel Biotech’s DNA-encoded compound library (DEL) technology with XtalPi’s AI platform, aiming to accelerate the…
•
China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic…
•
US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the opening of a 225,000 sq. ft. extension to its manufacturing facility in Durham, North Carolina. The expansion, which has received a USD1 billion investment, will focus on vaccine manufacturing and is a key part of MSD’s ongoing commitment…
•
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National Medical Products Administration (NMPA), this time for the treatment of moderate to severe hidradenitis suppurativa (HS). This IL-17A-targeted therapy previously gained approval in China for moderate-to-severe plaque psoriasis, ankylosing spondylitis, and active psoriatic arthritis (PsA).…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting significant revenue growth. In Q4, the company reported revenues of USD187 million, marking a 134.7% year-on-year increase. For the entire year, revenues surged by 120.0% to USD627 million. Carvykti’s Impact on RevenueThe BCMA-directed chimeric antigen…
•
Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to license sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Under the terms of the agreement, Ono has secured global development and commercialization rights to the drug. Terms of the AgreementOno will…
•
German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of Boehringer Ingelheim’s One Medicine Platform, enabled by the implementation of Veeva Development Cloud. This platform aims to streamline end-to-end processes and enhance information sharing across the organization. Strategic PartnershipThe collaboration between BI and Veeva began…
•
US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase III trial evaluating the efficacy and safety of its investigational drug felzartamab compared to placebo in adult kidney transplant recipients with late antibody-mediated rejection (AMR). This marks a significant step forward in addressing a critical…
•
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food and Drug Administration (FDA) to initiate a clinical study for its MRANK-106, a dual inhibitor of WEE1 and YES1 kinases. This marks a significant milestone for the company as it expands its innovative oncology pipeline…
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for its serum-free iterative rabies vaccine following the acquisition of the Drug Manufacturing License. The unblinded Phase III study results have demonstrated that the product meets the predetermined evaluation criteria for safety, immunogenicity, and immune persistence.…
•
China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured RMB500 million (USD69 million) in a Series E financing round. The investors include SSF Zhongguancun Independent Innovation Special Fund, Beijing Robotics Industry Development Investment Fund, and Qiming Venture Partners. This funding, the largest primary market…
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259)), has entered into a memorandum of understanding (MOU) with South Korea-based biotech company AbTis. This collaboration aims to enhance innovation in antibody-drug conjugate (ADC) therapeutics and…
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical study of its ASC47 in Australia. This adipose-targeted drug candidate, developed in-house, is designed to achieve weight loss without losing muscle mass. Clinical Study ResultsIn the study, ASC47 demonstrated a half-life of up to 26…